Related Experiment Video
Updated: Sep 10, 2025

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Leveraging phagocytosis using nanomedicines for cancer immunotherapy
Susam Lee1, Hoyeon Nam1, Katelyn Wahl2
1Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
Abstract:
Phagocytosis upregulation plays a crucial role in bridging to adaptive immunity for cancer immunotherapy. However, current approaches to modulating phagocytosis are beneficial to certain types of cancer only. In this Forum paper, we will highlight how nanoengineering can overcome the current limitation of phagocytosis-mediated cancer immunotherapy.
More Related Videos
05:06Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy
Published on: November 10, 2023
08:09Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
Phagocytosis